Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
30685-43-9
Molecular formula
C42H66O14
Molecular weight
795 g/mol
Drug class
Cardiac glycosidecardiotonic and antiarrhythmic agent
Mechanism of action
Inhibits myocardial Na+/K+-ATPase, increasing intracellular sodium and indirectly increasing intracellular calcium through reduced sodium-calcium exchange. This increases myocardial contractility and also enhances vagal tone, slowing atrioventricular conduction. Metildigoxin is demethylated to digoxin.
Indications / reported uses
Historical and jurisdiction-specific use for symptomatic treatment of selected cases of chronic heart failure and supraventricular arrhythmias, including atrial fibrillation; product availability and current use vary by country.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Metildigoxin Environmental Risk Assessment (ERA) (the Metildigoxin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.